Edition:
United States

Vita 34 AG (V3VGn.DE)

V3VGn.DE on Xetra

6.80EUR
24 May 2017
Change (% chg)

-- (--)
Prev Close
€6.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
8,182
52-wk High
€6.90
52-wk Low
€3.66

V3VGn.DE

Chart for V3VGn.DE

About

Vita 34 AG, is a Germany-based company that operates as an umbilical cord blood bank. It operates through the Stem Cell Storage and the Biotechnology segment. The Stem Cell Storage segment collects, processes, and stores stem cells from umbilical cord blood and umbilical cord tissue, as well as develops cell therapy procedures.... (more)

Overall

Beta: 0.04
Market Cap(Mil.): €19.19
Shares Outstanding(Mil.): 3.03
Dividend: 0.16
Yield (%): 2.52

Financials

  V3VGn.DE Industry Sector
P/E (TTM): 45.28 30.43 17.36
EPS (TTM): 0.14 -- --
ROI: 1.60 6.70 -5.72
ROE: 1.72 10.19 -5.10

BRIEF-Vita 34 Q1 EBITDA nearly doubling to EUR 0.7 million

* Q1 REVENUES INCREASED IN FIRST THREE MONTHS BY 7.1 PERCENT TO EUR 4.1 MILLION

May 16 2017

BRIEF-Vita 34 AG CFO Falk Neukirch has resigned

* Vita 34 AG: chief financial officer of Vita 34 AG to seek new challenges

May 01 2017

BRIEF-Vita 34 says to buy competitor Seracell Pharma

* dgap-adhoc: vita 34 ag: vita 34 concludes purchase agreement for the entire acquisition of its competitor seracell pharma ag

Apr 20 2017

BRIEF-Vita 34 FY revenues up 15 pct at 16.3 million euros

* FY sales revenues increased by 15.0 percent to 16.3 million euros following 14.2 million euros previous year

Mar 13 2017

BRIEF-Vita 34 FY sales revenues up at 16.2 million euros

* FY sales revenues increased in 2016 to a total of 16.2 million euros ($17.48 million)from 14.2 million euros achieved in commercial year 2015

Feb 01 2017

More From Around the Web

Earnings vs. Estimates